Divis Laboratories has secured a long-term contract to manufacture and supply pharmaceutical intermediates to a global partner, expecting significant revenue. They will invest ₹650-750 crore, funded by the customer, to expand capacity and bolster their custom synthesis position.

• Long-term supply agreement secured.
• ₹650-750 crore capacity expansion planned.
• No share exchange or related parties involved.